Celltrion Sets Out Timetable For Omalizumab Trials
Celltrion has set out a development timetable for its biosimilar omalizumab candidate that includes finishing a Phase III trial by 2022.
You may also be interested in...
BiosanaPharma has revealed success in a comparative Phase I trial for its BP001 omalizumab proposed biosimilar rival to Novartis’ Xolair.
To help fund Phase III clinical trials and US sales and marketing efforts respectively, Glenmark is looking for partners for both its omalizumab biosimilar candidate and its Ryaltris olopatadine and mometasone combination spray.
As the Fight The Fakes Alliance holds its fifth annual “Fight The Fakes Week,” the IGBA has signed to become a new member of the association as it calls for fresh action to prevent falsified medicines from reaching patients.